Abstract
Decades of basic and translational studies have identified the mechanisms by which pancreatic cancer cells use molecular pathways to hijack the normal homeostasis of the pancreas, promoting pancreatic cancer initiation, progression, and metastasis, as well as drug resistance. These molecular pathways were explored to develop targeted therapies to prevent or cure this fatal disease. Regrettably, the studies found that majority of the molecular events that dictate carcinogenic growth in the pancreas are non-actionable (potential non-responder groups of targeted therapy). In this review we discuss exciting discoveries on CCN-siblings that reveal how CCN-family members contribute to the different aspects of the development of pancreatic cancer with special emphasis on therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abraham SC, Wilentz RE, Yeo CJ, Sohn TA, Cameron JL, Boitnott JK, Hruban RH (2003) Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am J Surg Pathol 27:110-120
Abramson MA, Jazag A, van der Zee JA, Whang EE (2007) ThMahadevane molecular biology of pancreatic cancer. Gastrointestinal Cancer Res: GCR 1:S7-S12
Aguirre AJ et al. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112-3126. doi:10.1101/gad.1158703
Aguirre AJ et al. (2004) High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A 101:9067-9072. doi:10.1073/pnas.0402932101
Bailey JM et al. (2008) Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 14:5995-6004. doi:10.1158/1078-0432.CCR-08-0291
Ball DK, Rachfal AW, Kemper SA, Brigstock DR (2003) The heparin-binding 10 kDa fragment of connective tissue growth factor (CTGF) containing module 4 alone stimulates cell adhesion. J Endocrinol 176:R1-R7
Banerjee SK, Banerjee S (2012) CCN5/WISP-2: A micromanager of breast cancer progression. JCell CommunSignal 6:63-71. doi:10.1007/s12079-012-0158-2
Banerjee SK, Zoubine MN, Mullick M, Weston AP, Cherian R, Campbell DR (2000) Tumor angiogenesis in chronic pancreatitis and pancreatic adenocarcinoma: impact of K-ras mutations. Pancreas 20:248-255
Berman DM et al. (2003) Widespread requirement for hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425:846-851. doi:10.1038/nature01972
Blackstock AW et al. (2001) Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 7:3263-3268
Brigstock DR (1999) The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 20:189-206
Brigstock DR (2002) Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61. Angiogenesis 5:153-165
Brigstock DR (2003) The CCN family: a new stimulus package. J Endocrinol 178:169-175
Bullock AN, Fersht AR (2001) Rescuing the function of mutant p53 nature reviews. Cancer 1:68-76. doi:10.1038/35094077
Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE (1994) Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 54:3568-3573
Carr TH et al. (2016) Defining actionable mutations for oncology therapeutic development nature reviews. Cancer 16:319-329. doi:10.1038/nrc.2016.35
Charrier A, Brigstock DR (2013) Regulation of pancreatic function by connective tissue growth factor (CTGF, CCN2). Cytokine Growth Factor Rev 24:59-68. doi:10.1016/j.cytogfr.2012.07.001
Chen PP et al. (2007) Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2:e534. doi:10.1371/journal.pone.0000534
Chen J, Gao Y, Xu B, Cui X, Xu D (2014) NOV is upregulated and promotes migration and invasion in bladder cancer tumour biology: the journal of the international society for. Oncodevelopmental Biology and Medicine 35:6749-6755. doi:10.1007/s13277-014-1919-8
Chen CC, Kim KH, Lau LF (2016) The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. Oncogene 35:1314-1323. doi:10.1038/onc.2015.190
Conroy T et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825. doi:10.1056/NEJMoa1011923
Cui L et al. (2014) NOV promoted the growth and migration of pancreatic cancer cells. Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine 35:3195-3201. doi:10.1007/s13277-013-1418-3
Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524-7536. doi:10.1038/sj.onc.1206952
Davies SR, Watkins G, Mansel RE, Jiang WG (2007) Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol 14:1909-1918. doi:10.1245/s10434-007-9376-x
Davies SR, Davies ML, Sanders A, Parr C, Torkington J, Jiang WG (2010) Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer and the prognostic implications. Int J Oncol 36:1129-1136
Dhar G et al. (2007) Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymal-transition. Cancer Lett 254:63-70. doi:10.1016/j.canlet.2007.02.012
Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Vanveldhuizen PJ, Banerjee SK (2008) Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res 68:4580-4587. doi:10.1158/0008-5472.CAN-08-0316
Dobson JR et al. (2014) hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3. Cancer Cell Int 14:73. doi:10.1186/s12935-014-0073-0
Donnenberg VS, Meyer EM, Donnenberg AD (2009) Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells. Methods Mol Biol 568:261-279. doi:10.1007/978-1-59745-280-9_17
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23:1539-1548. doi:10.1038/sj.onc.1207272
Eser S, Schnieke A, Schneider G, Saur D (2014) Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer. doi:10.1038/bjc.2014.215
Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M (2015) Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim Biophys Acta 1853:89-100. doi:10.1016/j.bbamcr.2014.10.003
Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C (2004) Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 4:8. doi:10.1186/1471-2210-4-8
Goggins M (2005) Molecular markers of early pancreatic cancer. J Clin Oncol 23:4524-4531. doi:10.1200/JCO.2005.19.711
Griffin CA, Hruban RH, Long PP, Morsberger LA, Douna-Issa F, Yeo CJ (1994) Chromosome abnormalities in pancreatic adenocarcinoma Genes Chromosom Cancer 9:93-100
Grote T, Logsdon CD (2007) Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol 23:508-514. doi:10.1097/MOG.0b013e3282ba5724
Gupta N et al. (2001) Inhibition of glioma cell growth and tumorigenic potential by CCN3 (NOV). Mol Pathol: MP 54:293-299
Gurbuz I, Chiquet-Ehrismann R (2015) CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): a focus on its role in cancer. Int J Biochem Cell Biol 62:142-146. doi:10.1016/j.biocel.2015.03.007
Han H, Von Hoff DD (2013) SnapShot: pancreatic cancer. Cancer Cell 23:424-424e421. doi:10.1016/j.ccr.2013.03.008
Hanel W, Marchenko N, Xu S, Yu SX, Weng W, Moll U (2013) Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 20:898-909. doi:10.1038/cdd.2013.17
Haque I et al. (2011) Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol Cancer 10:8. doi:10.1186/1476-4598-10-8
Haque I et al. (2012) The matricellular protein CCN1/Cyr61 is a critical regulator of Sonic Hedgehog in pancreatic carcinogenesis. J Biol Chem 287:38569-38579. doi:10.1074/jbc.M112.389064
Hermann PC et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313-323. doi:10.1016/j.stem.2007.06.002
Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605-1617. doi:10.1056/NEJMra0901557
Hingorani SR et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469-483. doi:10.1016/j.ccr.2005.04.023
Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC Jr, Brekken RA, Fleming JB (2005) Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 200:371-377. doi:10.1016/j.jamcollsurg.2004.10.005
Huang H, Daniluk J, Liu Y, Chu J, Li Z, Ji B, Logsdon CD (2014) Oncogenic K-ras requires activation for enhanced activity. Oncogene 33:532-535. doi:10.1038/onc.2012.619
Huynh AS, Abrahams DF, Torres MS, Baldwin MK, Gillies RJ, Morse DL (2011) Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One 6:e20330. doi:10.1371/journal.pone.0020330
Ji Q et al. (2009) MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 4:e6816. doi:10.1371/journal.pone.0006816
Ji J, Jia S, Ji K, Jiang WG (2014) Wnt1 inducible signalling pathway protein-2 (WISP2/CCN5): roles and regulation in human cancers (review). Oncol Rep 31:533-539. doi:10.3892/or.2013.2909
Jun JI, Lau LF (2011) Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 10:945-963. doi:10.1038/nrd3599
Kanda M et al. (2012) Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 142:730-733e739. doi:10.1053/j.gastro.2011.12.042
Kanda M et al. (2013) Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association 11:719-730e715. doi:10.1016/j.cgh.2012.11.016
Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H (2003) Invasion and metastasis in pancreatic cancer. Mol Cancer 2:14
Kern SE, Hruban RH, Hidalgo M, Yeo CJ (2002) An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol Ther 1:607-613
Kong B, Michalski CW, Kleeff J (2009) Tumor initiating cells in pancreatic cancer: a critical view. World Journal of Stem Cells 1:8-10. doi:10.4252/wjsc.v1.i1.8
Lake AC, Castellot JJ Jr (2003) CCN5 modulates the antiproliferative effect of heparin and regulates cell motility in vascular smooth muscle cells. Cell Communication and Signaling : CCS 1:5. doi:10.1186/1478-811X-1-5
Lane DP, Hupp TR (2003) Drug discovery and p53. Drug Discov Today 8:347-355
Lang GA et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872. doi:10.1016/j.cell.2004.11.006
Lau LF (2012) CCN1 and CCN2: blood brothers in angiogenic action. Journal of Cell Communication and Signaling 6:121-123. doi:10.1007/s12079-012-0169-z
Lau LF (2016) Cell surface receptors for CCN proteins. Journal of Cell Communication and Signaling 10:121-127. doi:10.1007/s12079-016-0324-z
Leask A (2010) Yin and Yang part Deux: CCN5 inhibits the pro-fibrotic effects of CCN2. Journal of Cell Communication and Signaling 4:155-156. doi:10.1007/s12079-010-0092-0
Leask A (2011) CCN1: a novel target for pancreatic cancer. Journal of Cell Communication and Signaling 5:123-124. doi:10.1007/s12079-011-0127-1
Leask A (2013) Sonic advance: CCN1 regulates sonic hedgehog in pancreatic cancer. Journal of Cell Communication and Signaling 7:61-62. doi:10.1007/s12079-012-0187-x
Lee CJ, Dosch J, Simeone DM (2008a) Pancreatic cancer stem cells. J Clin Oncol 26:2806-2812. doi:10.1200/JCO.2008.16.6702
Lee CJ, Li C, Simeone DM (2008b) Human pancreatic cancer stem cells: implications for how we treat pancreatic cancer. Transl Oncol 1:14-18
Lehmann BD, Pietenpol JA (2012) Targeting mutant p53 in human tumors. J Clin Oncol 30:3648-3650. doi:10.1200/JCO.2012.44.0412
Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex nature reviews. Cancer 9:749-758. doi:10.1038/nrc2723
Li C et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030-1037. doi:10.1158/0008-5472.CAN-06-2030
Li J, Ye L, Owen S, Weeks HP, Zhang Z, Jiang WG (2015) Emerging Role of CCN Family Proteins in Tumorigenesis and Cancer Metastasis (Review) International Journal of Molecular Medicine 36:1451-1463. doi:10.3892/ijmm.2015.2390
Lin CG, Leu SJ, Chen N, Tebeau CM, Lin SX, Yeung CY, Lau LF (2003) CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem 278:24200-24208. doi:10.1074/jbc.M302028200
Mahadevan D, Von Hoff DD (2007) Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6:1186-1197. doi:10.1158/1535-7163.MCT-06-0686
Maitra A et al. (2002) Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 118:194-201. doi:10.1309/TPG4-CK1C-9V8V-8AWC
Maitra A et al. (2003) Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc 16:902-912. doi:10.1097/01.MP.0000086072.56290.FB
Maity G, Mehta S, Haque I, Dhar K, Sarkar S, Banerjee SK, Banerjee S (2014) Pancreatic tumor cell secreted CCN1/Cyr61 promotes endothelial cell migration and aberrant neovascularization. Sci Report 4:4995. doi:10.1038/srep04995
Marigo V, Johnson RL, Vortkamp A, Tabin CJ (1996) Sonic hedgehog differentially regulates expression of GLI and GLI3 during limb development. Dev Biol 180:273-283. doi:10.1006/dbio.1996.0300
Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, Blandino G (2014) Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene 33:1601-1608. doi:10.1038/onc.2013.106
Mazur PK, Siveke JT (2012) Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut 61:1488-1500. doi:10.1136/gutjnl-2011-300756
Merika EE, Syrigos KN, Saif MW (2012) Desmoplasia in pancreatic cancer. Can we fight it? Gastroenterol Res Pract 2012:781765. doi:10.1155/2012/781765
Mimeault M, Batra SK (2014) Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer. Research, Cosponsored by the American Society of Preventive Oncology 23:234-254. doi:10.1158/1055-9965.EPI-13-0785
Mohammed A, Janakiram NB, Pant S, Rao CV (2015) Molecular targeted intervention for pancreatic cancer. Cancer 7:1499-1542. doi:10.3390/cancers7030850
Montero AJ et al. (2012) Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat 132:215-223. doi:10.1007/s10549-011-1889-0
Nakahira S et al. (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. International Journal of Cancer Journal International Du Cancer 120:1355-1363. doi:10.1002/ijc.22390
Neesse A et al. (2013) CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A 110:12325-12330. doi:10.1073/pnas.1300415110
Olive KP, Tuveson DA (2006) The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 12:5277-5287. doi:10.1158/1078-0432.CCR-06-0436
Olive KP et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860. doi:10.1016/j.cell.2004.11.004
Olive KP et al. (2009) Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457-1461. doi:10.1126/science.1171362
Olivier M et al. (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157-1167. doi:10.1158/1078-0432.CCR-05-1029
Ono M et al. (2013) WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone. PLoS One 8:e71709. doi:10.1371/journal.pone.0071709
Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ (2011) Molecular characteristics of pancreatic ductal adenocarcinoma. Pathol Res Int 2011:620601. doi:10.4061/2011/620601
Perbal B (2001) The CCN family of genes: a brief history. Molecular Pathol: MP 54:103-104
Perbal B (2004) CCN proteins: multifunctional signalling regulators. Lancet 363:62-64. doi:10.1016/S0140-6736(03)15172-0
Perera RM, Bardeesy N (2012) Ready, set, go: the EGF receptor at the pancreatic cancer starting line. Cancer Cell 22:281-282. doi:10.1016/j.ccr.2012.08.019
Planque N, Perbal B (2003) A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 3:15. doi:10.1186/1475-2867-3-15
Reichert M, Rustgi AK (2011) Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest 121:4572-4578. doi:10.1172/JCI57131
Rhim AD et al. (2014) Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735-747. doi:10.1016/j.ccr.2014.04.021
Russo JW, Castellot JJ (2010) CCN5: biology and pathophysiology. Journal of Cell Communication and Signaling 4:119-130. doi:10.1007/s12079-010-0098-7
Sabbah M et al. (2011) CCN5, a novel transcriptional repressor of the transforming growth factor beta signaling pathway. Mol Cell Biol 31:1459-1469. doi:10.1128/MCB.01316-10
Saxena N, Banerjee S, Sengupta K, Zoubine MN, Banerjee SK (2001) Differential expression of WISP-1 and WISP-2 genes in normal and transformed human breast cell lines. Mol Cell Biochem 228:99-104
Simeone DM (2008) Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 14:5646-5648. doi:10.1158/1078-0432.CCR-08-0584
Soon LL, Yie TA, Shvarts A, Levine AJ, Su F, Tchou-Wong KM (2003) Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem 278:11465-11470. doi:10.1074/jbc.M210945200
Spivak-Kroizman TR et al. (2013) Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res 73:3235-3247. doi:10.1158/0008-5472.CAN-11-1433
Stromnes IM, Greenberg PD (2016) Pancreatic cancer: planning ahead for metastatic spread. Cancer Cell 29:774-776. doi:10.1016/j.ccell.2016.05.013
Takigawa M (2003) CTGF/Hcs24 as a multifunctional growth factor for fibroblasts, chondrocytes and vascular endothelial cells. Drug News & Perspectives 16:11-21
Thayer SP et al. (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851-856. doi:10.1038/nature02009
Tian C et al. (2007) Overexpression of connective tissue growth factor WISP-1 in Chinese primary rectal cancer patients. World J Gastroenterol: WJG 13:3878-3882
Ueda M et al. (2015) Clinical significance of expression of nephroblastoma overexpressed (NOV) in patients with colorectal cancer. Anticancer Res 35:6591-6597
Vaz AP, Ponnusamy MP, Batra SK (2013) Cancer stem cells and therapeutic targets: an emerging field for cancer treatment. Drug Delivery and Translational Research 3:113-120. doi:10.1007/s13346-012-0095-x
Von Hoff DD, Korn R, Mousses S (2009) Pancreatic cancer--could it be that simple? A different context of vulnerability. Cancer Cell 16:7-8. doi:10.1016/j.ccr.2009.06.011
Von Hoff DD et al. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703. doi:10.1056/NEJMoa1304369
Voutsadakis IA (2011) Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol 3:153-164. doi:10.4251/wjgo.v3.i11.153
Wang J, Zhang GY, Li XH (2006) Effect of indomethacin on Bfl-1, WISP-1 and proliferating cell nuclear antigen in colon cancer cell line HCT116 cells. Chin J Dig Dis 7:219-224. doi:10.1111/j.1443-9573.2006.00272.x
Wang-Gillam A et al. (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545-557. doi:10.1016/S0140-6736(15)00986-1
Weissmueller S et al. (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 157:382-394. doi:10.1016/j.cell.2014.01.066
Whatcott CJ, Posner RG, Von Hoff DD, Han H (2012) Desmoplasia and chemoresistance in pancreatic cancer. In: PJ G, HG M (eds) Pancreatic Cancer and Tumor Microenvironment. Trivandrum, India
Wilentz RE et al. (1998) Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 58:4740-4744
Wu L et al. (2014) CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene 33:504-513. doi:10.1038/onc.2012.602
Yang JY et al. (2015) High expression of WISP-1 correlates with poor prognosis in pancreatic ductal adenocarcinoma. Am J Transl Res 7:1621-1628
Ying H et al. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149:656-670. doi:10.1016/j.cell.2012.01.058
Yu C, Le AT, Yeger H, Perbal B, Alman BA (2003) NOV (CCN3) regulation in the growth plate and CCN family member expression in cartilage neoplasia. J Pathol 201:609-615. doi:10.1002/path.1468
Zhang L et al. (1997) Gene expression profiles in normal and cancer cells. Science 276:1268-1272
Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8:806-823. doi:10.1038/nrd2137
Acknowledgments
We would like to thank other members of our cancer research unit for valuable and helpful comments on this manuscript. We would also like to thank LaCoiya Harris for editing and organizing this manuscript. This work was supported by the Kansas City Area Life Science grant award (SKB), Merit review grant from Department of Veterans Affairs (SKB, 5I01BX001989-03 and SB,1I01BX001002-04), and KUMC Van Goethem Family Endowed Funds (SKB).
Author contributions
Snigdha Banerjee and Sushanta K. Banerjee performed the literature search and wrote the manuscript. Inamul Haque, Gargi Maity, Vijayalaxmi Gupta, Sandipto Sarkar and Arnab Ghosh revised it critically for important intellectual content. Donald Campbell and Daniel Von Hoff provided expert comments and editing.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflicts of interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Banerjee, S.K., Maity, G., Haque, I. et al. Human pancreatic cancer progression: an anarchy among CCN-siblings. J. Cell Commun. Signal. 10, 207–216 (2016). https://doi.org/10.1007/s12079-016-0343-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12079-016-0343-9